AstraZeneca Share Chat (AZN)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
AstraZeneca	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-11.00p	-0.23%	4,763.00p	4,763.00p	4,764.00p	4,787.00p	4,742.50p	4,772.50p	608,602	13:46:20

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	18,627.4	2,876.5	224.3	23.2	60,282.46

AstraZeneca Share Discussion Threads

Showing 10426 to 10447 of 10450 messages

Chat Pages: 418 417 416 415 414 413 412 411 410 409 408 407 Older

Date	Subject	Author	Discuss
18/9/2017 11:43	I think its GS had a negative note on Astra.	montyhedge	Read Full Thread Reply
17/9/2017 19:26	buywell FTSE 100 alert issued 7100 coming next week followed by 6750 within 4 weeks as of today Reasons why posted on BARC AZN chart IMO like that of BARC in now starting another leg down as it is on every chart I have looked at this evening BARC ,RBS ,LLOY ,BP. , SIA , GNK and now AZN FTSE 100 at 6750 should equate to a retest of 4380p AZN IMO $29 in the US dyor	buywell3	Read Full Thread Reply
07/9/2017 19:21	Heading towards the very big gap	holts	Read Full Thread Reply
07/9/2017 11:56	the new asthma drug looks promising.	careful	Read Full Thread Reply
03/9/2017 17:53	can expect a pullback from a chart point of view, if current pattern is to be continued, North Korea likely to influence markets tomorrow, expecting 4480 to give support, but external factors can blow any charts out the window	nocky44	Read Full Thread Reply
03/9/2017 09:13	Alp - Don't always agree with you but that post is bang on the money.	ianood	Read Full Thread Reply
02/9/2017 11:59	Nothing new here. IP has always been an issue. Generics will nearly always appear once big sellers go off patent. The strength of the IP protection has always been important. No lessons to be learnt.	alphorn	Read Full Thread Reply
01/9/2017 12:29	Re GSK or AZN Why not try both?	marksp2011	Read Full Thread Reply
11/8/2017 10:48	Hmm. This is the first post of the trading week and I have nothing to say.	grahamite2	Read Full Thread Reply
05/8/2017 07:32	Neurological diseases like Alzheimers' are being wrongly diagnosed They are forms of CJD caused by prions ..... it is a MASSIVE cover up read this hTTps://www.thetyee.ca/Documents/2017/06/24/Risk-Advisory-Opinion-CWD-2017.pdf then this hTTp://crossbowcommunications.com/wildlife-contracting-brain-disease-from-biosolids/	buywell3	Read Full Thread Reply
02/8/2017 15:00	M, would be interesting. GSK X for 19 pence tomorrow from memory. Agree with Woodford's comment on liberal amounts of full valuations currently. I'm often too cautious though. Edit, GSK XD is next Thursday.	essentialinvestor	Read Full Thread Reply
02/8/2017 14:03	Happy to compare notes in 12-18mnths romeike Your GSK against my RB. and AZN equivalent mix.	minerve	Read Full Thread Reply
02/8/2017 13:41	Rubbish, there is only one reason to hold AZ now over GSK and that is on the hope it will get bought out. May government will never see AZ sold off, just look at recent statements on this exact point. Current CEO should be begging investors for forgiveness for poo-pooing an AMAZING offer from Pfizer, shamelessly hyping AZ pipeline into the stratosphere. On the other hand, having seen Emma Walmsley at GSK in action, very impressive... If I want risk I'll go biotech thanks, better returns than anything AZ offers. Good luck all.	romeike	Read Full Thread Reply
02/8/2017 08:14	GSK have got work to do on the medium term pipeline, their advantage, for now, is having ample time for development with no major patent loses until 2026/7. AZN as a pure pharma play is higher risk/higher reward imv.	essentialinvestor	Read Full Thread Reply
01/8/2017 23:09	AZN all the way. Easy options deliver mediocre performance. Stick with your GSK, get your slippers and cocoa and enjoy the silence....	minerve	Read Full Thread Reply
01/8/2017 19:23	GSK has no imminent patent cliff Heading towards a wall is not trueAZ has sold all the family silver to fund new drugs that may or may not deliver - take your pick	mattboxy	Read Full Thread Reply
01/8/2017 14:48	"GSK is heading towards a brick wall" If that ISN'T the case then why the sudden desperate move to invest in pharma?	minerve	Read Full Thread Reply
01/8/2017 13:31	"GSK is heading towards a brick wall" - What trash. GSK is growing, AZN not so much.	romeike	Read Full Thread Reply
31/7/2017 15:48	Astra is the one again on bid list plenty of upside	nw99	Read Full Thread Reply
31/7/2017 15:20	"Think Woodford sold the wrong Big Pharma. Beware the dead cat bounce. Soriot gone by Christmas." No. Definetely not. GSK is heading towards a brick wall.	minerve	Read Full Thread Reply
31/7/2017 14:59	Think Woodford sold the wrong Big Pharma. Beware the dead cat bounce. Soriot gone by Christmas.	romeike	Read Full Thread Reply
30/7/2017 19:12	Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend."	nw99	Read Full Thread Reply

Chat Pages: 418 417 416 415 414 413 412 411 410 409 408 407 Older